Nilotinib Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Nilotinib Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
236
Registered trials
284
Result records
51
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Nilotinib Hydrochloride can convert its Small molecule drug profile and CSF-1R x DDR1 x c-Kit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Nilotinib Hydrochloride (query alias: nilotinib) |
|---|---|
| Modality / target | Small molecule drug; CSF-1R x DDR1 x c-Kit; CSF-1R antagonists, DDR1 antagonists, c-Kit inhibitors |
| Highest global status | Approved |
| Originator | Novartis Pharma AG |
| Active developers | Xspray Pharma AB, Totalclarity, Inc., Azurity Pharmaceuticals, Inc. |
The MCP disease footprint includes Aggressive-Phase Chronic Myelocytic Leukemia, Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07493408 | Phase 2 | Not yet recruiting | 45 | Morphological relapse-free survival (M-RFS) |
| NCT07138378 | Phase 1 | Completed | 128 | Bioavailability (Peak Plasma Concentration (Cmax)) of XS003 versus Tasigna treatment |
| NCT07413263 | Not Applicable | Not yet recruiting | 75 | Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Phase 2; n=75; evaluation: not stated. Reported fields: AE = 65 events ; -; AE = 57 events
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
Phase 2; n=21; evaluation: not stated. Reported fields: Baseline (within 6 weeks prior to the start of treatment) = 0 proportion of participants (95% Confidence Interval, 0 - 0); Baseline (within 6 weeks prior to the start of treatment) = 0 proportion of participants (95% Confidence Interval, 0 - 0); -
Cardiovascular toxicity of second-generation TKIs versus imatinib in first-line chronic myeloid leukemia: An updated systematic review and meta-analysis.
Not Applicable; n=1944; evaluation: Negative. Reported fields: all-cause mortality: RR = 1.28(95.0% CI, 0.85 - 1.92), P-Value = 0.24; all-cause mortality: RR = 1.28(95.0% CI, 0.85 - 1.92), P-Value = 0.24
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Nilotinib Hydrochloride addresses Aggressive-Phase Chronic Myelocytic Leukemia, Accelerated phase Philadelphia chromosome positive chronic myeloid leukemia, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 51 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CSF-1R x DDR1 x c-Kit records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-12-22 | 上海海和生物与石药集团携手推进新药研发新篇章 | Phase 2 | Financial terms not disclosed |
| 2025-06-12 | Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions | Approved | Financial terms not disclosed |
| 2025-03-06 | 拜耳医药授予亿帆医药拜万戈和多吉美在中国的独家市场推广权益 | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Pharmaceutical compositions comprising nilotinib”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
